<DOC>
	<DOCNO>NCT01394276</DOCNO>
	<brief_summary>This observational study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) clinical practice patient moderate severe rheumatoid arthritis . Data collect patient 12 month follow first infusion RoActemra/Actemra .</brief_summary>
	<brief_title>An Observational Study RoActemra/Actemra ( Tocilizumab ) Clinical Practice Patients With Rheumatoid Arthritis ( TRUST )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Rheumatoid arthritis diagnose accord American College Rheumatology ( ACR ) criterion Initiated RoActemra/Actemra treatment accord Summary Product Characteristics 6 month open study center Current serious infection Hypersensitivity active component excipients Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>